Mabwell Signed Cooperation Agreement with Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Mabwell Signed Cooperation Agreement with Shanghai Institute of Materia Medica, Chinese Academy of Sciences Release time：Mar 24, 2020

In August, 2016，Mabwell (Shanghai) signed a cooperation agreement with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences on development of antibody drug conjugates with new linkers.

Hot News

Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA
Mabwell Published First-in-Human Study Results of Novel Anti-ST2 Monoclonal Antibody 9MW1911 at ERS 2025
Mabwell Announces First Patient Dosed in the US Phase II Study of 9MW3011
Mabwell Bioscience, Insilico Medicine, and ChemExpress Forging Ahead with ADC Innovation Through Strategic Collaboration
New Drug Application of Mabwell's 9MW0813 for Injection Accepted by NMPA